Gerald Simonneau
Overview
Explore the profile of Gerald Simonneau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
388
Citations
30586
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gerges C, Jevnikar M, Brenot P, Savale L, Beurnier A, Bouvaist H, et al.
Circ Cardiovasc Interv
. 2025 Feb;
18(2):e014785.
PMID: 39965044
Background: Riociguat and balloon pulmonary angioplasty (BPA) improve hemodynamics in inoperable chronic thromboembolic pulmonary hypertension. Importantly, comparative effects of riociguat and BPA on different components of right ventricular (RV) afterload...
2.
Delcroix M, Pepke-Zaba J, DArmini A, Fadel E, Guth S, Hoole S, et al.
Circulation
. 2024 Sep;
150(17):1354-1365.
PMID: 39286890
Background: The European Chronic Thromboembolic Pulmonary Hypertension (CTEPH) registry, conducted between 2007 and 2012, reported the major impact of pulmonary endarterectomy (PEA) on the long-term survival of patients with CTEPH....
3.
Kim N, DArmini A, Delcroix M, Jais X, Jevnikar M, Madani M, et al.
Eur Respir J
. 2024 Aug;
64(4).
PMID: 39209473
Chronic thromboembolic pulmonary hypertension is a complication of pulmonary embolism and a treatable cause of pulmonary hypertension. The pathology is a unique combination of mechanical obstruction due to failure of...
4.
Humbert M, Galie N, Rubin L, Simonneau G, McLaughlin V
Eur Respir J
. 2024 Aug;
64(4).
PMID: 39209470
No abstract available.
5.
Gerges C, Beurnier A, Jais X, Herve P, Lau E, Girerd B, et al.
Chest
. 2024 Jul;
166(5):1173-1183.
PMID: 39059577
Background: Exercise hemodynamics are recommended for early detection of pulmonary arterial hypertension (PAH) and have been suggested to be predictive of future development of PAH in high-risk populations such as...
6.
Boucly A, Bertoletti L, Fauvel C, Dewavrin M, Gerges C, Grynblat J, et al.
Respir Med Res
. 2024 Jul;
86:101123.
PMID: 38972109
Pulmonary hypertension (PH) continues to present significant challenges to the medical community, both in terms of diagnosis and treatment. The advent of the updated 2022 European Society of Cardiology (ESC)...
7.
Benza R, Simonneau G, Ghofrani H, Corris P, Langleben D, Rosenkranz S, et al.
J Heart Lung Transplant
. 2024 Jun;
43(10):1756-1760.
PMID: 38852934
In Riociguat rEplacing PDE5i therapy evaLuated Against Continued PDE5i thErapy (REPLACE) (NCT02891850), improvements in risk status were observed in patients with pulmonary arterial hypertension (PAH) at intermediate risk switching to...
8.
Grynblat J, Khouri C, Hlavaty A, Jais X, Savale L, Chaumais M, et al.
Eur Respir J
. 2024 May;
63(6).
PMID: 38697649
Background: Pulmonary arterial hypertension (PAH) has been described in patients treated with proteasome inhibitors (PIs). Our objective was to evaluate the association between PIs and PAH. Methods: Characteristics of incident...
9.
Ghofrani H, Simonneau G, DArmini A, Fedullo P, Howard L, Jais X, et al.
Lancet Respir Med
. 2024 Mar;
12(4):e21-e30.
PMID: 38548406
Background: Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar. Methods: The phase 2, double-blind,...
10.
Benza R, Grunig E, Sandner P, Stasch J, Simonneau G
Eur Respir Rev
. 2024 Mar;
33(171).
PMID: 38508664
The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway plays a key role in the pathogenesis of pulmonary hypertension (PH). Targeted treatments include phosphodiesterase type 5 inhibitors (PDE5i)...